Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOESTRIN 24 FE vs ESTROSTEP FE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive. Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration. Alters endometrial development, decreasing implantation likelihood.
Combination estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone acetate produces progestational effects including endometrial transformation and cervical mucus thickening, inhibiting sperm penetration and implantation.
FDA-approved: Prevention of pregnancy.,Off-label: Treatment of acne vulgaris, regulation of menstrual disorders, dysmenorrhea.
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no known contraindications, who have achieved menarche)
One tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 24 days, followed by a low-dose iron-containing tablet (75 mg ferrous fumarate) for 4 days.
One tablet daily orally, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (24 active tablets) followed by ferrous fumarate 75 mg tablets (4 placebo tablets).
Norethindrone: 5-12 hours; Ethinyl estradiol: 13-27 hours. The terminal half-life supports once-daily dosing; steady state is achieved within 5-7 days.
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours. Clinical context: Steady-state reached within 7-10 days.
Ethinyl estradiol undergoes CYP3A4-mediated hydroxylation and glucuronidation; norethindrone is metabolized via reduction, glucuronidation, and sulfation, primarily by CYP3A4 and CYP2E1.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Norethindrone acetate: hydrolyzed to norethindrone, then metabolized by reduction and glucuronidation.
Ethinyl estradiol and norethindrone are primarily excreted in urine (about 50-60%) and feces (about 30-40%) as glucuronide and sulfate conjugates after hepatic metabolism.
Renal: ~40% as metabolites; fecal: ~30% (biliary); remainder as conjugates.
Norethindrone: ~97% bound, primarily to sex hormone-binding globulin (SHBG) and albumin. Ethinyl estradiol: ~97% bound, primarily to albumin and SHBG.
Ethinyl estradiol: 97-98% bound to albumin and SHBG; norethindrone acetate: 91-95% bound to albumin and SHBG.
Norethindrone: approximately 3.6 L/kg; Ethinyl estradiol: approximately 2.7 L/kg. Large Vd indicates extensive tissue distribution (reproductive organs, liver, fat).
Ethinyl estradiol: 2.3-3.6 L/kg; norethindrone acetate: 1.5-2.5 L/kg. Indicates extensive tissue distribution.
Norethindrone: approximately 64% (oral) due to first-pass metabolism. Ethinyl estradiol: approximately 55% (oral) due to first-pass metabolism and intestinal conjugation.
Oral: Ethinyl estradiol ~45% (first-pass metabolism); norethindrone acetate ~64%.
No dosage adjustment required for mild to moderate renal impairment. Not recommended for use in patients with severe renal impairment or end-stage renal disease due to lack of data.
No dose adjustment is recommended for patients with mild to moderate renal impairment. Use is contraindicated in patients with severely impaired renal function (GFR <30 m L/min/1.73 m²) due to potential for fluid retention and hyperkalemia.
Contraindicated in patients with hepatic disease, including acute hepatitis, hepatic adenomas, or cirrhosis. No dose adjustment recommendations; avoid use.
Contraindicated in patients with acute or chronic hepatic dysfunction (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh class A), use with caution and monitor liver function; no specific dose adjustment guidelines are established.
Approved for use in postmenarchal females. Dosage same as adults: one active tablet daily for 24 days followed by iron-containing tablets for 4 days. Not indicated for premenarchal females.
Safety and efficacy have not been established in pediatric patients below 16 years of age. Post-pubertal adolescents may be dosed as adults, with careful consideration of risks (e.g., bone density).
Not indicated for use in postmenopausal women. No specific dosing recommendations; therapy should be discontinued if menopause occurs.
Not indicated for use in women over 65 years due to lack of efficacy and safety data, and increased risk of cardiovascular and thrombotic events.
Cigarette smoking increases risk of serious cardiovascular events (thrombosis, myocardial infarction, stroke) from combination oral contraceptives, especially in women over 35 who smoke >15 cigarettes/day.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and smoking intensity (especially >35 years). Women >35 years who smoke should not use this product.
Thrombotic disorders, hypertension, gallbladder disease, hepatic neoplasia, retinal thrombosis, carbohydrate/lipid effects, headache, menstrual irregularities, depression, hereditary angioedema.
Thromboembolic disorders, cardiovascular disease (MI, stroke), hypertension, gallbladder disease, hepatic neoplasia, lipid effects, glucose intolerance, headache, breakthrough bleeding, depression, contact lens intolerance, fluid retention, hereditary angioedema.
Thrombophlebitis/thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected pregnancy, undiagnosed abnormal genital bleeding, known/suspected breast cancer, hepatic tumors (benign/malignant), hypersensitivity to any component, smoking >15 cigarettes/day in women >35 years.
Thrombophlebitis or thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected breast carcinoma, endometrial carcinoma or other estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, cholestatic jaundice of pregnancy or jaundice with prior pill use, hepatic adenoma or carcinoma, pregnancy, hypersensitivity to any component.
No specific food interactions. Grapefruit juice may increase ethinyl estradiol levels; avoid excessive consumption. Alcohol does not affect efficacy but may worsen side effects like nausea or dizziness. The ferrous fumarate in placebo pills may be absorbed better with vitamin C (e.g., orange juice).
No specific food interactions are reported for Estrostep Fe. Grapefruit juice may slightly increase estrogen levels but is not considered clinically significant. There are no dietary restrictions. However, patients should maintain a consistent intake of folic acid if planning pregnancy; iron supplements can be taken with food to reduce GI upset.
First trimester: Postmarketing studies have not shown an increased risk of birth defects with oral contraceptives. Second and third trimesters: Contraindicated due to potential adverse effects on fetal development including possible estrogenic effects on fetal genitalia. Discontinue if pregnancy occurs.
Category X. Estrostep FE (norethindrone acetate/ethinyl estradiol/ferrous fumarate) is contraindicated in pregnancy. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects from sex hormones. Second/third trimester: feminization of male fetus, potential for urogenital malformations, and long-term reproductive tract effects. Postnatal: possible increased risk of childhood cancers.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio not established. Use may reduce milk production and composition. Not recommended during breastfeeding; consider alternative contraception.
Excreted in breast milk in small amounts (estrogen M/P ratio ~0.2, progestin M/P ratio ~0.6). May reduce milk quantity and quality. Use caution; generally not recommended. No adverse effects reported in infants at typical doses.
No dosing adjustments are applicable as Loestrin 24 Fe is contraindicated during pregnancy. Discontinue immediately upon pregnancy confirmation.
Contraindicated; no dose adjustment needed because drug should be discontinued immediately if pregnancy occurs. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) not applicable due to contraindication.
Loestrin 24 Fe contains norethindrone acetate and ethinyl estradiol with 24 active tablets and 4 ferrous fumarate placebo tablets. It is approved for contraception and acne vulgaris in women ≥16 years. The shortened hormone-free interval (4 vs 7 days) may reduce breakthrough bleeding and improve ovarian suppression. Counsel patients that the iron tablets are not active hormone and serve only to maintain routine. If a dose is missed, the patient should take the missed pill as soon as remembered and continue the remaining pills, possibly requiring backup contraception. Breakthrough bleeding is common in the first few cycles; rule out pregnancy if persistent.
Estrostep Fe is a combined oral contraceptive containing norethindrone acetate and ethinyl estradiol. It is unique among OCPs for its step-up estrogen regimen (20, 30, 35 mcg EE) intended to mimic natural menstrual cycle. Clinicians should note that it is not FDA-approved for acne treatment, though it is often used off-label; only Estrostep (non-Fe) is approved for acne. The iron (ferrous fumarate) in the last 7 tablets is a placebo. It is a low-dose pill; missed doses more likely cause breakthrough bleeding. Contraindications include smoking >35, history of DVT/PE, migraine with aura, liver disease, breast cancer. Counsel patients to take at same time daily; if missed, follow standard missed pill protocol.
Take one pill daily at the same time, preferably after a meal to reduce nausea.,The 4 brown pills contain iron; they are not hormonal and are taken during the placebo week.,Use backup contraception (condoms) for the first 7 days if starting for the first time or after a break.,Missing pills increases risk of pregnancy; follow package instructions for missed doses.,Do not smoke while taking this medication, especially if over 35 years old, due to increased risk of blood clots.,Report severe abdominal pain, chest pain, shortness of breath, headache, visual changes, or leg pain/swelling.,Regular gynecological exams and blood pressure monitoring are recommended.,Store at room temperature away from moisture and heat.
Take one pill at the same time each day. The first 21 pills contain active hormones; the last 7 pills are iron tablets (not hormones).,If you miss a pill, refer to the package insert or contact your healthcare provider. Use backup contraception (condoms) if pills are missed.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding, especially in the first few months.,Estrostep Fe does not protect against sexually transmitted infections (STIs). Always use condoms for STI prevention.,Smoking while using this pill increases risk of serious cardiovascular events. Do not smoke.,Contact your doctor if you experience signs of a blood clot: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache.,The iron in the last 7 pills is to help with iron levels but does not provide hormonal contraception during that week.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOESTRIN 24 FE vs ESTROSTEP FE, answered by our medical review team.
LOESTRIN 24 FE is a Combined Oral Contraceptive that works by Combination estrogen-progestin contraceptive. Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration. Alters endometrial development, decreasing implantation likelihood.. ESTROSTEP FE is a Combined Oral Contraceptive that works by Combination estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone acetate produces progestational effects including endometrial transformation and cervical mucus thickening, inhibiting sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOESTRIN 24 FE and ESTROSTEP FE depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOESTRIN 24 FE is: One tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 24 days, followed by a low-dose iron-containing tablet (75 mg ferrous fumarate) for 4 days.. The standard adult dose of ESTROSTEP FE is: One tablet daily orally, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (24 active tablets) followed by ferrous fumarate 75 mg tablets (4 placebo tablets).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOESTRIN 24 FE and ESTROSTEP FE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOESTRIN 24 FE is classified as Category C. First trimester: Postmarketing studies have not shown an increased risk of birth defects with oral contraceptives. Second and third trimesters: Contraindicated due to potential adv. ESTROSTEP FE is classified as Category C. Category X. Estrostep FE (norethindrone acetate/ethinyl estradiol/ferrous fumarate) is contraindicated in pregnancy. First trimester: increased risk of neural tube defects, cardiov. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.